Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MPO | P05164 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.41 |
| ▸ | KDM5C | P41229 | 2/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998832 | 0.87 | KDM4E (0.64) | CYP1A2POLBKDM4ECYP3A4MPO | |
| SCHEMBL16572977 | 0.86 | CYP1A2 (0.56) | CYP1A2POLBKDM4ECYP3A4PRKCI | |
| SCHEMBL17920368 | 0.85 | KDM5A (0.55) | CYP1A2POLBKDM4ECYP3A4PRKCI | |
| Ethionamide SCHEMBL15798363 | 0.84 | CYP1A2 (0.71) | CYP1A2POLBKDM4ECYP3A4MPO | |
| SCHEMBL2405138 | 0.83 | KDM4E (0.51) | CYP1A2POLBKDM4ECYP3A4MPO | |
| 2-Ethylisonicotinamide SCHEMBL2606610 | 0.82 | CYP1A2 (0.69) | CYP1A2POLBKDM4ECYP3A4PRKCI | |
| SCHEMBL2989476 | 0.82 | KDM4E (0.47) | CYP1A2POLBKDM4ECYP3A4MPO | |
| SCHEMBL17555380 | 0.82 | CYP1A2 (0.62) | CYP1A2POLBKDM4ECYP3A4PRKCI | |
| SCHEMBL28289385 | 0.82 | KDM4E (0.50) | CYP1A2POLBKDM4ECYP3A4MPO | |
| SCHEMBL4009980 | 0.82 | KDM4E (0.50) | CYP1A2POLBKDM4ECYP3A4MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112955546-B | Human interleukin 10 variant and derivative thereof | 江苏恒瑞医药股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-112955546-A | Human interleukin 10 variant and its derivative | 江苏恒瑞医药股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-102333779-B | Benzopyran and benzoxex PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-09 | — | — | CN | disclosed |
| CN-102482258-B | Alpha helix mimetics and methods relating thereto | PRISM BIOLAB CORP | 2014-06-25 | — | — | CN | disclosed |
| CN-103517904-A | Alpha-helix mimetics and methods relating thereto | PRISM BIOLAB CORP | 2014-01-15 | — | — | CN | disclosed |
| CN-101631560-B | Use of pegylated IL-10 to treat cancer | MERCK SHARP & DOHME | 2013-12-25 | — | — | CN | disclosed |
| CN-103288753-A | Cyclopenta [D] pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-09-11 | — | — | CN | disclosed |
| CN-101516891-B | Dihydrothieno pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-06-05 | — | — | CN | disclosed |
| CN-101631778-B | Cyclopenta [ D ] pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-05-08 | — | — | CN | disclosed |
| CN-102482258-A | Alpha helix mimetics and methods relating thereto | PRISM BIOLAB CORP | 2012-05-30 | — | — | CN | disclosed |
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | BRIDGE BIORESEARCH RIGHTS (JERSEY) LIMITED (GB) | 2010-07-22 | — | — | US | disclosed |
| CN-101631560-A | Use of pegylated IL-10 to treat cancer | SCHERING CORP | 2010-01-20 | — | — | CN | disclosed |
| CN-101516891-A | Dihydrothieno pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2009-08-26 | — | — | CN | disclosed |
| CN-101511842-A | Dihydrofuro pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2068873-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | Pharma 2100 (DK) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031440-A2 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | PHARMA 2100 (DK) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184811-A1 | ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS | ODC1, OTC, ACACB | CYP1A2 385/4885POLB 2027/4885KDM4E 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.